WO2011031955A3 - Optical monitoring of leukemia - Google Patents

Optical monitoring of leukemia Download PDF

Info

Publication number
WO2011031955A3
WO2011031955A3 PCT/US2010/048409 US2010048409W WO2011031955A3 WO 2011031955 A3 WO2011031955 A3 WO 2011031955A3 US 2010048409 W US2010048409 W US 2010048409W WO 2011031955 A3 WO2011031955 A3 WO 2011031955A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
subject
leukemia
optical
monitoring
Prior art date
Application number
PCT/US2010/048409
Other languages
French (fr)
Other versions
WO2011031955A2 (en
Inventor
Raghavan Rajagopalan
Richard B. Dorshow
Original Assignee
Mallinckrodt Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc. filed Critical Mallinckrodt Inc.
Publication of WO2011031955A2 publication Critical patent/WO2011031955A2/en
Publication of WO2011031955A3 publication Critical patent/WO2011031955A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to compounds, methods and devices for targeting of optical agents to leukemia affected cells or tissues in a subject. Compounds of the invention include conjugates and bioconjugates comprising a targeting moiety and an optical agent. In an aspect of the invention, the targeting moiety is an amino acid sequence which preferentially binds to leukemia cells. In another aspect of the invention, the optical agent is an imaging agent derived from a pyrazine, azulene, or azaazulene dye. In a further aspect of the invention, the optical agent may comprise a photosensitizer. Some methods of the invention relate to administration, activation, and/or monitoring of compounds of the invention. In an aspect, a compound of the invention is administered to a subject, allowed time to target a leukemia affected cell or tissue in the subject, and the fluorescence intensity of the compound in the subject is measured. Some devices of the invention include means for activation, detection and monitoring of compounds of the invention. In an aspect of the invention, a device includes an electromagnetic radiation source, collector, and detector.
PCT/US2010/048409 2009-09-11 2010-09-10 Optical monitoring of leukemia WO2011031955A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24161109P 2009-09-11 2009-09-11
US61/241,611 2009-09-11

Publications (2)

Publication Number Publication Date
WO2011031955A2 WO2011031955A2 (en) 2011-03-17
WO2011031955A3 true WO2011031955A3 (en) 2011-06-23

Family

ID=43269564

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/048409 WO2011031955A2 (en) 2009-09-11 2010-09-10 Optical monitoring of leukemia

Country Status (1)

Country Link
WO (1) WO2011031955A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371555B2 (en) 2012-06-01 2016-06-21 Concordia Laboratories Inc. Lighting systems and methods of using lighting systems for in vitro potency assay for photofrin

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010070A2 (en) * 2004-07-10 2006-01-26 Board Of Regents, The University Of Texas System Compositions and methods related to peptides that selectively bind leukemia cells
WO2006071759A2 (en) * 2004-12-23 2006-07-06 Mallinckrodt Inc. Fluorescent pyrazine derivatives and methods of using the same in assessing renal function
WO2007106436A2 (en) * 2006-03-10 2007-09-20 Mallinckrodt Inc. Photoactive compounds and compositions and uses thereof
WO2007149478A2 (en) * 2006-06-22 2007-12-27 Mallinckrodt Inc. Pyrazine derivatives with extended conjugation and uses thereof
WO2008108941A2 (en) * 2007-03-01 2008-09-12 Mallinckrodt Inc. Integrated photoactive peptides and uses thereof
WO2009018405A1 (en) * 2007-07-31 2009-02-05 Mallinckrodt Inc. Integrated photoactive agents and uses thereof
WO2009061473A2 (en) * 2007-11-07 2009-05-14 Mallinckrodt Inc. Photonic shell-core cross linked and functionalized nanostructures for biological applications

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US5698397A (en) 1995-06-07 1997-12-16 Sri International Up-converting reporters for biological and other assays using laser excitation techniques
US5672333A (en) 1996-05-13 1997-09-30 Mallinckrodt Medical, Inc. Delta1,6 bicyclo 4,4,0! functional dyes for contrast enhancement in optical imaging
US6929807B1 (en) 1996-08-09 2005-08-16 Mannatech, Inc. Compositions of plant carbohydrates as dietary supplements
US6228344B1 (en) 1997-03-13 2001-05-08 Mallinckrodt Inc. Method of measuring physiological function
WO1999039738A1 (en) 1998-02-09 1999-08-12 Bracco Research S.A. Targeted delivery of biologically active media
US6167297A (en) 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
US7235685B2 (en) 2001-07-03 2007-06-26 Mallinckrodt, Inc. Aromatic sulfenates for type I phototherapy
US6180086B1 (en) 2000-01-18 2001-01-30 Mallinckrodt Inc. Hydrophilic cyanine dyes
US6748259B1 (en) 2000-06-15 2004-06-08 Spectros Corporation Optical imaging of induced signals in vivo under ambient light conditions
US6838074B2 (en) 2001-08-08 2005-01-04 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US6761878B2 (en) 2001-10-17 2004-07-13 Mallinckrodt, Inc. Pathological tissue detection and treatment employing targeted benzoindole optical agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010070A2 (en) * 2004-07-10 2006-01-26 Board Of Regents, The University Of Texas System Compositions and methods related to peptides that selectively bind leukemia cells
WO2006071759A2 (en) * 2004-12-23 2006-07-06 Mallinckrodt Inc. Fluorescent pyrazine derivatives and methods of using the same in assessing renal function
WO2007106436A2 (en) * 2006-03-10 2007-09-20 Mallinckrodt Inc. Photoactive compounds and compositions and uses thereof
WO2007149478A2 (en) * 2006-06-22 2007-12-27 Mallinckrodt Inc. Pyrazine derivatives with extended conjugation and uses thereof
WO2008108941A2 (en) * 2007-03-01 2008-09-12 Mallinckrodt Inc. Integrated photoactive peptides and uses thereof
WO2009018405A1 (en) * 2007-07-31 2009-02-05 Mallinckrodt Inc. Integrated photoactive agents and uses thereof
WO2009061473A2 (en) * 2007-11-07 2009-05-14 Mallinckrodt Inc. Photonic shell-core cross linked and functionalized nanostructures for biological applications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAGHAVAN RAJAGOPALAN ET AL: "Novel type 1 photosensitizers: viability of leukemia cells exposed to reactive intermediates generated in situ by in vitro photofragmentation", PROCEEDINGS OF THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING (SPIE); 20090611, vol. 7380, 13 July 2009 (2009-07-13), pages 738027/1 - 8, XP009140796, ISSN: 0277-786X, [retrieved on 20090713], DOI: DOI:10.1117/12.822840 *

Also Published As

Publication number Publication date
WO2011031955A2 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
Han et al. Upconversion nanoparticles/hyaluronate–rose bengal conjugate complex for noninvasive photochemical tissue bonding
US10548997B2 (en) Fluorescent silica-based nanoparticles
Punjabi et al. Amplifying the red-emission of upconverting nanoparticles for biocompatible clinically used prodrug-induced photodynamic therapy
CA2900363C (en) Multimodal silica-based nanoparticles
Nkepang et al. Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor
Wang et al. NIR scaffold bearing three handles for biocompatible sequential click installation of multiple functional arms
Kim et al. Photosensitizer-conjugated polymeric nanoparticles for redox-responsive fluorescence imaging and photodynamic therapy
Lai et al. Special reactive oxygen species generation by a highly photostable BODIPY-based photosensitizer for selective photodynamic therapy
Xiong et al. A singlet oxygen self-reporting photosensitizer for cancer phototherapy
US20200155710A1 (en) Sulfur- or heavy atom-containing nanoparticles, methods of making same, and uses thereof
Zheng et al. Near-infrared light-excited upconverting persistent nanophosphors in vivo for imaging-guided cell therapy
EP2303337A1 (en) Small molecule ligand-drug conjugates for targeted cancer therapy
WO2012021015A3 (en) Method for simultaneously detecting fluorescence and raman signals for multiple fluorescence and raman signal targets, and medical imaging device for simultaneously detecting multiple targets using the method
Wei et al. High-sensitivity in vivo imaging for tumors using a spectral up-conversion nanoparticle NaYF4: Yb 3+, Er 3+ in cooperation with a microtubulin inhibitor
Villa et al. Functionalized scintillating nanotubes for simultaneous radio-and photodynamic therapy of cancer
WO2006060797A3 (en) Mri guided photodynamic therapy for cancer
François et al. Fluorescence diagnosis of bladder cancer: a novel in vivo approach using 5‐aminolevulinic acid (ALA) dendrimers
Chi et al. Loading drugs in natural phospholipid bilayers of cell membrane shells to construct biomimetic nanocomposites for enhanced tumor therapy
Maiti et al. Rose Bengal Decorated NaYF4: Tb Nanoparticles for Low Dose X-ray-Induced Photodynamic Therapy in Cancer Cells
WO2011031955A3 (en) Optical monitoring of leukemia
Saenz et al. Charged groups on pyropheophorbide-based photosensitizers dictate uptake by tumor cells and photodynamic therapy efficacy
Vandana et al. Synergistic activity of combination therapy with PEGylated pemetrexed and gemcitabine for an effective cancer treatment
US11607454B2 (en) Devices and processes for Cherenkov-activated nuclear-targeted photodynamic therapy
Xu et al. Dual Tumor-Selective β-Carboline-Based Fluorescent Probe for High-Contrast/Rapid Diagnosis of Clinical Tumor Tissues
KR101375349B1 (en) Complex of hydrophilic photosensitizer and biocompatible polymer for useful photodynamic diagnosis or therapy and process of preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10761082

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10761082

Country of ref document: EP

Kind code of ref document: A2